Combining antagonists of the IL-6 pathway with other treatment approaches holds promise for enhancing efficacy and improving patient outcomes [45], and ongoing clinical trials are evaluating the safety and efficacy of IL-6 inhibition in cancer patients [44]. The gene discussed is IL6; the disease is cancer.